Imuldosa (Ustekinumab)

Ustekinumab binds to the p40 subunit shared by interleukin‑12 and interleukin‑23, blocking these cytokines from activating their receptors. This inhibition dampens the Th1 and Th17 pathways, decreasing the release of inflammatory mediators that drive the symptoms of psoriasis, arthritis, and Crohn’s disease.

The dosing regimen for Imuldosa is individualized by the prescribing clinician based on the patient’s condition, weight, and response. The prescriber determines the initial loading dose and any subsequent maintenance doses, following approved labeling and clinical guidelines.

Safety data for ustekinumab in pregnancy and lactation are limited. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider, who can weigh disease control against any unknown fetal or infant exposure.

To request Imuldosa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and any required import documentation.

Imuldosa (ustekinumab) targets the IL‑12/23 pathway, whereas anti‑TNF agents block tumor necrosis factor and newer IL‑23‑specific antibodies (e.g., guselkumab) focus solely on IL‑23. Clinical studies suggest comparable efficacy in psoriasis, with a distinct safety profile; choice of therapy depends on patient history, comorbidities, and physician preference.

Imuldosa must be stored refrigerated at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking. If the product reaches room temperature, it should be used within the time frame specified in the labeling.

Imuldosa is given as a subcutaneous injection, typically by a healthcare professional. The initial dose is administered as a loading injection, followed by maintenance injections at intervals defined by the prescriber. Patients should be observed for any immediate adverse reactions after each injection.

The most serious risks include severe infections such as tuberculosis, opportunistic infections, and reactivation of latent infections. Rare but important concerns are malignancies (e.g., lymphoma), hypersensitivity reactions including anaphylaxis, and possible worsening of inflammatory bowel disease.

Imuldosa is contraindicated in individuals with known hypersensitivity to ustekinumab or any of its excipients. It should also be avoided in patients with active, serious infections, uncontrolled tuberculosis, or those receiving live vaccines. Clinicians must evaluate each patient’s medical history before initiating therapy.